Serum Cell Division Cycle 42 before and after Programmed Death-1 Inhibitor Therapy in Advanced Melanoma Patients: Correlation with Tumor Features, Clinical Response, and Survival

Serum Cell Division Cycle 42 before and after Programmed Death-1 Inhibitor Therapy in Advanced Melanoma Patients: Correlation with Tumor Features, Clinical Response, and Survival

Ling Zhang,¹ Shenglan Zhang,² Zhao Han,¹ Zhao Liu,¹ Yanyan Xu,¹ Xiaojing Li,¹ Guoying Miao¹ and Liang Niu¹

¹Dermatology Center, Affiliated Hospital of Hebei Engineering University, Handan, Hebei, China
²Medical Department, HanDan Central Hospital, Handan, Hebei, China

Cell division cycle 42 (CDC42) mediates immune escape in cancers. This study aimed to investigate linkages of CDC42 with tumor features, treatment response, and survival in advanced melanoma patients receiving programmed death-1 (PD-1) inhibitors. Pre-treatment and post-treatment (after 2 cycles) serum CDC42 of 35 advanced melanoma patients receiving PD-1 inhibitor was assessed by enzyme-linked immunosorbent assay.P = 0.029 and OS (HR: 7.749,<00A0>P<00A0>= 0.005)]. Elevated CDC42 correlates with advanced TNM, abnormal LDH, worse clinical response, and dismal survival in advanced melanoma patients receiving PD-1 inhibitors.

Key words —— advanced melanoma; cell division cycle 42; clinical response and survival; programmed death-1 inhibitor; tumor feature

===============================

Tohoku J. Exp. Med., 2024 February, 262(2), 133-141.

Correspondence: Liang Niu, Dermatology Center, Affiliated Hospital of Hebei Engineering University, No. 81, Congtai Road, Congtai District, Handan, Hebei 056000, China.

e-mail: liangmi499393590@163.com